Vertex Pharmaceuticals Inc/ US92532F1003 /
24/05/2024 22:00:00 | Chg. +6.1500 | Volume | Bid01:59:51 | Ask01:59:51 | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
456.9500USD | +1.36% | 1.05 mill. Turnover: 270.95 mill. |
450.8000Bid Size: 100 | 465.4500Ask Size: 100 | 117.92 bill.USD | - | 32.52 |
GlobeNewswire
15/05
Third Harmonic Bio Announces First Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
09/05
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
GlobeNewswire
08/05
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
GlobeNewswire
08/05
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo ...
GlobeNewswire
07/05
Prelude Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
30/04
American Kidney Fund Encourages People to Be APOL1 Aware with First Annual APOL1-Mediated Kidney Dis...
GlobeNewswire
27/04
SHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLC Investigates MODN, AIRC, INRD, ALPN
GlobeNewswire
22/04
TAKE ACTION: The M&A Class Action Firm Launches Legal Inquiry for the Merger - ALPN, LABP, SWAV, FUS...
GlobeNewswire
22/04
CRISPR Therapeutics to Present Oral Presentation at the American Society of Gene & Cell Therapy (ASG...
GlobeNewswire
09/04
American Kidney Fund and Alonzo Mourning Call for More Awareness and Understanding of APOL1-Mediated...
GlobeNewswire
03/04
CRISPR Therapeutics to Present at the Annual Needham Virtual Healthcare Conference
GlobeNewswire
01/04
CervoMed Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Updates
GlobeNewswire
01/04
CRISPR Therapeutics to Present at the American Society of Gene & Cell Therapy (ASGCT) 2024 Annual Me...
GlobeNewswire
15/03
American Kidney Fund Announces 2024 Class of Corporate Members Providing Support in the Fight Agains...
GlobeNewswire
13/03
Entrada Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results